Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion · Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseIschaemia-reperfusionCerebral (MCAO/stroke)BALB/cMale
Model: Permanent middle cerebral artery occlusion (pMCAO), permanent focal cerebral ischaemia
Compound C reduced p-AMPK, LC3 and Beclin-1, raised p-mTOR, and significantly reduced neurological deficits, infarct area and brain water content 24 hours after occlusion.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
MouseChemical/toxinC57BL/6Male
Model: Acute wood smoke inhalation exposure in mice, with parallel in vitro exposure of primary human bronchial epithelial cells to wood smoke extract
Acute wood smoke exposure promoted AMPK phosphorylation, macrophage inflammatory protein 2 expression and lung inflammation in mice, all of which were reduced by Compound C treatment. The work positions NADPH oxidase-dependent, reactive oxygen species-sensitive AMPK signalling as the pathway drivin…
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.
